NMAD

The reported transaction involved the Reporting Person's receipt of 15,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 15,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

The total reported in Column 5 includes (i) the 15,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

The reported transaction involved the Reporting Person's receipt of 350,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 350,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

The total reported in Column 5 includes (i) the 350,000 newly awarded RSUs, and (ii) 350,000 RSUs, all of which have vested.

The reported transaction involved the Reporting Person's receipt of 15,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 15,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

The total reported in Column 5 includes (i) the 15,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

The reported transaction involved the Reporting Person's receipt of 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

The total reported in Column 5 includes (i) the 50,000 newly awarded RSUs, and (ii) 50,000 RSUs, all of which have vested.

The reported transaction involved the Reporting Person's receipt of 40,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 40,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

The total reported in Column 5 includes (i) the 40,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

The reported transaction involved the Reporting Person's receipt of 30,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 30,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

The total reported in Column 5 includes (i) the 30,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

Represents a grant of 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The RSUs shall vest 25% on May 29, 2026, and 25% on the last date of each subsequent calendar quarter thereafter until fully vested.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 350,000 options (the "Options") granted to the Reporting Person on July 3, 2025. In exchange for the Options, the Reporting Person received 350,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 350,000 RSUs vest immediately upon grant.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 350,000 options (the "Options") granted to the Reporting Person on July 3, 2025. In exchange for the Options, the Reporting Person received 350,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 350,000 RSUs vest immediately upon grant.

The canceled Options provided for vesting 50% on the effective date, 25% on September 30,2025 and 25% on December 31,2025.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on August 15, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

The canceled Options provided for vesting 50% on the grant date, the remaining 50% vesting in equal installments of 12.5% on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on August 15, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

The canceled Options provided for vesting 50% on the grant date, the remaining 50% vesting in equal installments of 12.5% on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on August 15, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

The canceled Options provided for vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on August 15, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

The canceled Options provided for vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 50,000 options (the "Options") granted to the Reporting Person on September 1, 2025. In exchange for the Options, the Reporting Person received 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vest immediately upon grant.

The canceled Options provided for vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026.

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 50,000 options (the "Options") granted to the Reporting Person on September 1, 2025. In exchange for the Options, the Reporting Person received 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vest immediately upon grant.

Fifty percent (50%) of the option vested and became exercisable on the grant date. The remaining fifty percent (50%) vests in equal installments of twelve and one-half percent (12.5%) on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested, subject to the reporting person's continuous service through each applicable vesting date.

Fifty percent (50%) of the option vested and became exercisable on the grant date. The remaining fifty percent (50%) vests in equal installments of twelve and one-half percent (12.5%) on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested, subject to the reporting person's continuous service through each applicable vesting date.

Effective September 1, 2025, the reporting person was granted stock options to purchase 50,000 shares vesting vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026., subject to continuous service and acceleration upon the occurrence of certain events. The grant was in connection with the reporting person being appointed as the Company's Chief Financial Officer. The exercise price is $4.45 per share.

Effective August 15, 2025, the reporting person was granted stock options to purchase 25,000 shares vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested, subject to continuous service. The grant was in connection with the reporting person being appointed to the Company's Board of Directors. The exercise price is $3.59 per share.

Effective August 15, 2025, the reporting person was granted stock options to purchase 25,000 shares vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested, subject to continuous service. The grant was in connection with the reporting person being appointed to the Company's Board of Directors. The exercise price is $3.59 per share.

Effective July 3, 2025, the reporting person was granted stock options to purchase an aggregate of 350,000 shares vesting 50% on the effective date, 25% on September 30,2025 and 25% on December 31,2025. The grant was a signing bonus for the reporting person entering into an employment agreement with the issuer. The exercise price is $2.83 per share.

Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.

Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.

Effective June 30, 2025 the reporting person was granted stock options in aggregate of 12,600 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.

Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.

Effective June 30, 2025 the reporting person was granted stock options to purchase an aggregate of 10,662 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective June 30, 2025 the reporting person was granted stock options in aggregate of 7,754 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective June 30, 2025 the reporting person was granted stock options in aggregate of 11,632 vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 9,508 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 8,777 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 5,851 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 8,045 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 4,166 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 3,030 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 4,924 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 4,545 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Effective September 30, 2024, the reporting person was granted stock options to purchase an aggregate of 5,786 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.